MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

First Patient Enrolled in Post-Approval Study for HF Therapy

Image courtesy of Impulse Dynamics First Patient Enrolled in Post-Approval Study for HF Therapy
Optimizer Smart System
Impulse Dynamics closed out 2019 by raising $80.3M in a series D round. Now the MT. Laurel, N.J.-based company is moving quickly in 2020 by enrolling the first patient in its post-approval study of the Optimizer system, which delivers Cardiac Contractility Modulation therapy.

Impulse Dynamics has enrolled the first patient in a post-approval study of the Cardiac Contractility Modulation therapy, which is delivered by the Optimizer system. The move comes a few months after the private firm raised $80.3 million in a series D round.

The MT. Laurel, N.J.-based company said the post-approval study will evaluate the real-world evidence of the therapy’s safety and efficacy for three years. About 620 patients from heart centers across the U.S. will be enrolled in the study.

The first patient was enrolled by Charles Jost, MD, interventional cardiologist and principal investigator at Southwest Cardiovascular Associates in Mesa, AZ.

“Before the Optimizer system was introduced, many of my heart failure patients had few, or no effective options to improve their quality of life available to them,” said Dr. Jost. “The positive clinical outcomes for patients treated with this therapy are impressive and it has given many of my patients a reason to be hopeful again. I am pleased to participate in this study because it seeks to further substantiate the compelling portfolio of clinical evidence that supported the Optimizer system’s FDA approval in actual clinical practice over time.”

The firm’s technology delivers Cardiac Contractility Modulation (CCM). Through CCM an electrical pulse is delivered during the absolute refractory period, which is just after heart contracts. In contrast to a pacemaker or defibrillator, CCM works by modulating the strength of the heart muscle contraction rather than the rhythm.

The Optimizer Smart device received breakthrough device designation in 2015 and eventually won FDA approval in March of 2019. The technology went before the Circulatory System Devices Panel of the Medical Devices Advisory Committee, Dec. 4, 2018, receiving a 12-0 vote on the benefit-to-risk ratio of the device.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.